Prospects of immune checkpoint modulators in the treatment of glioblastoma

Nature Reviews Neurology

Volumn 11, Issue 9, 2015, Pages 504-514

  Preusser, Matthias ^a   Lim, Michael ^b   Hafler, David A ^c   Reardon, David A ^d   Sampson, John H ^e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE NEW HAVEN HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMP 224; AMP 514; ANTINEOPLASTIC AGENT; AVELUMAB; BEVACIZUMAB; BMS 936559; BMS 986016; CORTICOSTEROID; DEXAMETHASONE; DURVALUMAB; IMMUNE CHECKPOINT MODULATOR; IMP 321; IPH 2101; IPILIMUMAB; LIRILUMAB; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TEMOZOLOMIDE; TICILIMUMAB; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BLADDER CANCER; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BRAIN EDEMA; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; BREAST METASTASIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; COLORECTAL CANCER; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ENDOCRINE DISEASE; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HODGKIN DISEASE; HUMAN; HYPOPHYSITIS; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; INFLAMMATION; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TOXICITY; LYMPHOCYTOPENIA; LYMPHOMA; MELANOMA; MERKEL CELL TUMOR; MESOTHELIOMA; METASTATIC MELANOMA; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; SKIN DISEASE; SMALL CELL LUNG CANCER; SOLID TUMOR; STEREOTACTIC RADIOSURGERY; STOMACH CANCER; TREATMENT RESPONSE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; ADVERSE EFFECTS; ANIMAL; BRAIN NEOPLASMS; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES;

ANIMALS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY;

EID: 84941025149     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2015.139     Document Type: Review

References (114)

1. Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 16 (Suppl. 4), iv1-iv63 (2014
2. Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699-708 (2014
3. Temodar (temozolomide) [prescribing information]. http://www.merck.com/product/usa/pi-circulars/t/temodar-capsules/temodar-pi.pdf (Merck & Co., Inc. 2014).
4. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005
5. Omuro, A. M., Faivre, S. & Raymond, E. Lessons learned in the development of targeted therapy for malignant gliomas. Mol. Cancer Ther. 6, 1909-1919 (2007
6. Woehrer, A., Bauchet, L. & Barnholtz-Sloan, J. S. Glioblastoma survival: has it improved?. Evidence from population-based studies. Curr. Opin. Neurol. 27, 666-674 (2014
7. Weller, M. et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 15, e395-e403 (2014
8. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010
9. ODay, S. J. et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-Arm phase II study. Ann. Oncol. 21, 1712-1717 (2010
10. Topalian, S. L. et al. Safety, activity, and immune correlates of anti PD 1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
11. Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013
12. Ansell, S. M. et al. PD 1 blockade with nivolumab in relapsed or refractory Hodgkins lymphoma. N. Engl. J. Med. 372, 311-319 (2015
13. Motzer, R. J. et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J. Clin. Oncol. 33, 1430-1437 (2015
14. Rizvi, N. A. et al. Activity and safety of nivolumab, an anti PD 1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non small cell lung cancer (CheckMate 063): A phase 2, single-Arm trial. Lancet Oncol. 16, 257-265 (2015
15. Opdivo (nivolumab) [prescribing information]. http://www.opdivo.bmscustomerconnect.com/gateway (Bristol-Myers Squibb Company, 2014
16. Keytruda (pembrolizumab) [prescribing information]. http://www.merck.com/product/usa/pi-circulars/k/keytruda/keytruda-pi.pdf (Merck & Co., Inc. 2015
17. Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 39, 1-10 (2013
18. Driessens, G., Kline, J. & Gajewski, T. F. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol. Rev. 229, 126-144 (2009
19. Jackson, C., Ruzevick, J., Phallen, J., Belcaid, Z. & Lim, M. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin. Dev. Immunol. 2011, 1-21 (2011
20. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12, 252-264 (2012
21. Bakdash, G., Sittig, S. P., Van Dijk, T., Figdor, C. G. & De Vries, I. J. The nature of activatory and tolerogenic dendritic cell-derived signal II. Front. Immunol. 4, 53 (2013
22. Joller, N. et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J. Immunol. 186, 1338-1342 (2011
23. Hastings, W. D. et al. TIM 3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur. J. Immunol. 39, 2492-2501 (2009
24. Tarhini, A. A. & Iqbal, F. CTLA 4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther. 3, 15-25 (2010
25. Margolin, K. et al. Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol. 13, 459-465 (2012
26. Queirolo, P. et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J. Neurooncol. 118, 109-116 (2014
27. Yervoy (ipilimumab) [prescribing information]. http://www.yervoy.com (Bristol-Myers Squibb Company, 2013
28. Di Giacomo, A. M. et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT M1): An open-label, single-Arm phase 2 trial. Lancet Oncol. 13, 879-886 (2012
29. Luke, J. J. & Ott, P. PD 1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 6, 3479-3492 (2015
30. Weber, J. S. et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 31, 4311-4318 (2013
31. Robert, C. et al. Anti programmed death receptor 1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet. 384, 1109-1117 (2014
32. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti PD 1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013
33. Antonia, S. J. et al. Nivolumab (anti PD 1; BMS 936558, ONO 4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 32 (15 Suppl.), 8113 (2014
34. Antonia, S. J. et al. Nivolumab (anti PD 1; BMS 936558, ONO 4538) and ipilimumab in first-line NSCLC: Interim phase I results. J. Clin. Oncol. 32 (15 Suppl.), 8023 (2014
35. Gettinger, S. N. et al. First-line nivolumab (anti PD 1; BMS 936558, ONO 4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD L1 status. J. Clin. Oncol. 32 (15 Suppl.), 8024 (2014
36. Rizvi, N. A. et al. Safety and response with nivolumab (anti PD 1; BMS 936558, ONO 4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J. Clin. Oncol. 32 (15 Suppl.), 8022 (2014
37. Garon, E. B. et al. Safety and clinical activity of MK 3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 32 (15 Suppl.), 8020 (2014
38. Hafler, D. A. & Kuchroo, V. TIMs: central regulators of immune responses. J. Exp. Med. 205, 2699-2701 (2008
39. Anderson, A. C. Tim 3: An emerging target in the cancer immunotherapy landscape. Cancer Immunol. Res. 2, 393-398 (2014
40. Sierro, S., Romero, P. & Speiser, D. E. The CD4-like molecule LAG 3, biology and therapeutic applications. Expert Opin. Ther. Targets. 15, 91-101 (2011
41. Woo, S. R. et al. Immune inhibitory molecules LAG 3 and PD 1 synergistically regulate T cell function to promote tumoral immune escape. Cancer Res. 72, 917-927 (2012
42. Downey, S. G. et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-Associated antigen 4 blockade. Clin. Cancer Res. 13, 6681-6688 (2007
43. Juszczak, A., Gupta, A., Karavitaki, N., Middleton, M. R. & Grossman, A. B. Ipilimumab: A novel immunomodulating therapy causing autoimmune hypophysitis: A case report and review. Eur. J. Endocrinol. 167, 1-5 (2012
44. Weber, J. S. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am. Soc. Clin. Oncol. Educ. Book 174-177 (2012
45. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015
46. Dranoff, G. Immunotherapy at large: balancing tumor immunity and inflammatory pathology. Nat. Med. 19, 1100-1101 (2013
47. Fecher, L. A., Agarwala, S. S., Hodi, F. S. & Weber, J. S. Ipilimumab and its toxicities: A multidisciplinary approach. Oncologist. 18, 733-743 (2013
48. Heimberger, A B. & Sampson, J. H. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?. Neuro Oncol. 13, 3-13 (2011
49. Raizer, J. Issues in developing drugs for primary brain tumors: barriers and toxicities. Toxicol. Pathol. 39, 152-157 (2011
50. Taube, J. M. et al. Association of PD 1, PD 1 ligands, and other features of the tumor immune microenvironment with response to anti PD 1 therapy. Clin. Cancer Res. 20, 5064-5074 (2014
51. Snyder, A. et al. Genetic basis for clinical response to CTLA 4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014
52. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD 1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015
53. Vauleon, E., Avril, T., Collet, B., Mosser, J. & Quillien, V. Overview of cellular immunotherapy for patients with glioblastoma. Clin. Dev. Immunol. 2010 (2010
54. Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. Nature http://dx.doi.org/10.1038/nature14432
55. Reardon, D. A. et al. Immunotherapy advances for glioblastoma. Neuro Oncol. 16, 1441-1458 (2014
56. Muller, C. et al. Hematogenous dissemination of glioblastoma multiforme. Sci. Transl. Med. 6, 247ra101 (2014
57. Preusser, M. Neuro-oncology: A step towards clinical blood biomarkers of glioblastoma. Nat. Rev. Neurol. 10, 681-682 (2014
58. Tran, T. T. et al. Inhibiting TGF-β signaling restores immune surveillance in the SMA 560 glioma model. Neuro Oncol. 9, 259-270 (2007
59. Wainwright, D. A. et al. Durable therapeutic efficacy utilizing combinatorial blockade against, IDO, CTLA 4, and PD L1 in mice with brain tumors. Clin. Cancer Res. 20, 5290-5301 (2014
60. Parsa, A. T. et al. Loss of tumor suppressor PTEN function increases B7 H1 expression and immunoresistance in glioma. Nat. Med. 13, 84-88 (2007
61. Fecci, P. E. et al. Increased regulatory T cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66, 3294-3302 (2006
62. Ooi, Y. C. et al. The role of regulatory T cells in glioma immunology. Clin. Neurol. Neurosurg. 119, 125-132 (2014
63. Mirghorbani, M., Van Gool, S. & Rezaei, N. Myeloid-derived suppressor cells in glioma. Expert Rev. Neurother. 13, 1395-1406 (2013
64. Vlahovic, G., Fecci, P. E., Reardon, D. & Sampson, J. H. Programmed death-ligand 1(PD L1) as an immunotherapy target in patients with glioblastoma. Neuro Oncol. 17, 1043-1045 (2015
65. Berghoff, A. S. et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 17, 1064-1075 (2014
66. Bloch, O. et al. Gliomas promote immunosuppression through induction of B7 H1 expression in tumor-Associated macrophages. Clin. Cancer Res. 19, 3165-3175 (2013
67. Velcheti, V. et al. Programmed death ligand 1 expression in non-small cell lung cancer. Lab. Invest. 94, 107-116 (2014
68. Doucette, T. et al. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol. Res. 1, 112-122 (2013
69. Bhat, K. P. et al. Mesenchymal differentiation mediated by NF ?B promotes radiation resistance in glioblastoma. Cancer Cell 24, 331-346 (2013
70. Avril, T. et al. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand 1 (PDL 1) and indoleamine 2, 3-dioxygenase (IDO) on tumour-specific T cell functions. J. Neuroimmunol. 225, 22-33 (2010
71. Wintterle, S. et al. Expression of the B7-related molecule B7 H1 by glioma cells: A potential mechanism of immune paralysis. Cancer Res. 63, 7462-7467 (2003
72. Magnus, T. et al. Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J. Neurosci. 25, 2537-2546 (2005
73. Berghoff, A. S. et al. PD1 (CD279) and PD L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin. Neuropathol. 33, 42-49 (2014
74. Berghoff, A. S. et al. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD L1) in melanoma brain metastases. Histopathology. 66, 289-299 (2015
75. Berghoff, A. S. et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunol (in press). (2015
76. Han, S. et al. Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma. Br. J. Cancer 110, 2560-2568 (2014
77. Yue, Q. et al. The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J. Neurooncol. 116, 251-259 (2014
78. Rutledge, W. C. et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin. Cancer Res. 19, 4951-4960 (2013
79. Kjaergaard, J. et al. Therapeutic efficacy of OX 40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 60, 5514-5521 (2000
80. Fecci, P. E. et al. Systemic CTLA 4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T cell function. Clin. Cancer Res. 13, 2158-2167 (2007
81. Reardon, D. A. et al. Immune checkpoint blockade for glioblastoma: Preclinical activity of single agent and combinatorial therapy. J. Clin. Oncol. 32 (15 Suppl.), 2084 (2014
82. Zeng, J. et al. Anti PD 1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 86, 343-349 (2013
83. Belcaid, Z. et al. Focal radiation therapy combined with 4-1BB activation and CTLA 4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS ONE 9, e101764 (2014
84. Schumacher, T. et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 512, 324-327 (2014
85. Schuster, J. et al. A phase II, multicenter trial of rindopepimut (CDX 110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 17, 854-861 (2015
86. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499, 214-218 (2013
87. Chaichana, K. L., Pinheiro, L. & Brem, H. Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas. Ther. Deliv. 6, 353-369 (2015
88. Sims, J. S., Ung, T. H., Neira, J. A., Canoll, P. & Bruce, J. N. Biomarkers for glioma immunotherapy: the next generation. J. Neurooncol. 3, 359-372 (2015
89. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009
90. Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009
91. Ribas, A., Chmielowski, B. & Glaspy, J. A. Do we need a different set of response assessment criteria for tumor immunotherapy?. Clin. Cancer Res. 15, 7116-7118 (2009
92. Wolchok, J. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann. Oncol. 23, (Suppl. 8) viii15-viii21 (2012
93. Nishino, M. et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin. Cancer Res. 19, 3936-3943 (2013
94. Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963-1972 (2010
95. Papadatos-Pastos, D., Soultati, A. & Harries, M. Targeting brain metastases in patients with melanoma. Biomed. Res. Int. 2013, 186563 (2013
96. Park, B., Yee, C. & Lee, K. M. The effect of radiation on the immune response to cancers. Int. J. Mol. Sci. 15, 927-943 (2014
97. Frey, B. et al. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies. Curr. Med. Chem. 19, 1751-1764 (2012
98. Grossman, S. A. et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin. Cancer Res. 17, 5473-5480 (2011
99. Grimaldi, A. M. et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 3, e28780 (2014
100. Nicholas, S. et al. Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors. Brain Tumor Res. Treat. 1, 2-8 (2013
101. Stupp, R. et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 2712-2718 (2010
102. Zitvogel, L. et al. The anticancer immune response: indispensable for therapeutic success?. J. Clin. Invest. 118, 1991-2001 (2008
103. Sampson, J. H. et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 13, 324-333 (2011
104. Sanchez-Perez, L. A. et al. Myeloablative temozolomide enhances CD8(+) T cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS ONE 8, e59082 (2013
105. Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002
106. Avastin (bevacizumab) [prescribing information]. http://www.gene.com/download/pdf/avastin-prescribing.pdf (Genentech, Inc. 2014
107. Mansfield, A. S., Nevala, W. K., Lieser, E. A., Leontovich, A. A. & Markovic, S. N. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology 2, e24436 (2013
108. Terme, M. et al. Modulation of immunity by antiangiogenic molecules in cancer. Clin. Dev. Immunol. 2012, 8 (2012
109. Nishino, M., Giobbie-Hurder, A., Ramaiya, N. H. & Hodi, F. S. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J. Immunother. Cancer 2, 40 (2014
110. Schaff, L. R. et al. Ipilimumab for recurrent glioblastoma (GBM). J. Clin. Oncol. 32 (15 Suppl.). 32, e13026 (2014
111. Chinot, O. L. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709-722 (2014
112. Kaal, E. C. & Vecht, C. J. The management of brain edema in brain tumors. Curr. Opin. Oncol. 16, 593-600 (2004
113. Hempen, C., Weiss, E & Hess, C. F. Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects?. Support Care Cancer 10, 322-328 (2002
114. Min, L., Vaidya, A. & Becker, C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur. J. Endocrinol. 164, 303-307 (2011